TriangleNCT02122172 · OUTCOME
Median Overall Survival (OS) Time
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- Up to 3 years
What was measured
Estimated using the Kaplan-Meier method.
Analysis population: Analysis population includes those in the main Phase II study
Groups in this outcome
Treatment (Afatinib)
Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. afatinib dimaleate: Given PO laboratory biomarker analysis: Correlative studies
| Group | Source count |
|---|---|
| Treatment (Afatinib) | 23 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Afatinib) | 5.3 | Not reported | 3.7 | 7.4 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 3.7
- upper Limit
- 7.4
- value
- 5.3
- denoms
- counts
- group Id
- OG000
- value
- 23
- units
- Participants
- description
- Estimated using the Kaplan-Meier method.
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. afatinib dimaleate: Given PO laboratory biomarker analysis: Correlative studies
- id
- OG000
- title
- Treatment (Afatinib)
- param Type
- MEDIAN
- population Description
- Analysis population includes those in the main Phase II study
- reporting Status
- POSTED
- time Frame
- Up to 3 years
- title
- Median Overall Survival (OS) Time
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice